Isaac Eliaz
Principal investigator, leads Eliaz Therapeutics, Inc..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$2.9MFederal grants as PI3 awards
11Patents grantedLatest Jul 7, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $2.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 24, 2023 | NIH | SBIR Phase II Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI | $991K | Eliaz Therapeutics, Inc. |
| Jun 6, 2022 | NIH | SBIR Phase II Depleting Circulating Galectin-3 with Therapeutic Apheresis: A NovelTreatment for Sepsis/AKI | $1.7M | Eliaz Therapeutics, Inc. |
| Sep 1, 2018 | NIH | SBIR Phase I Depleting Circulating Galectin-3 with Therapeutic Apheresis: A Novel Treatment for Sepsis/AKI. | $225K | Eliaz Therapeutics, Inc. |
12 patents as inventor
- US 10213462Eliaz Therapeutics, Inc.Feb 26, 2019
- US 10828413Eliaz Therapeutics, Inc.Nov 10, 2020
- US 10953148Eliaz Therapeutics, Inc.Mar 23, 2021
- US 11141431Eliaz Therapeutics, Inc.Oct 12, 2021
- US 11389476Eliaz Therapeutics, Inc.Jul 19, 2022
- US 11389477Eliaz Therapeutics, Inc.Jul 19, 2022
- US 11389478Eliaz Therapeutics, Inc.Jul 19, 2022
- US 12109346Eliaz Therapeutics, Inc.Oct 8, 2024
- US 12551503Eliaz Therapeutics, Inc.Feb 17, 2026
- US 12673146Eliaz Therapeutics, Inc.Jul 7, 2026
- US 9549953Eliaz Therapeutics, Inc.Jan 24, 2017
- US Eliaz Therapeutics, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#717
Awards as PI#927
Patents#6
Companies
- Eliaz Therapeutics, Inc.Leads (SEC Form D) · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.